Scholarlink

<p>Nuclear reactions between proton irradiation and boron via p + <sup>11</sup>B→3α (boron proton-capture reaction; BPCR) and n + <sup>10</sup>B→α+<sup>7</sup>Li (boron neutron-capture reaction; BNCR) enhance the cell-killing effects of proton beam irradiation (PBI); however, which reaction exerts superior sensitization effects remains unclear. Therefore, we evaluated the efficacy of the BPCR and BNCR in enhancing the cell-killing effects of PBI. Human osteosarcoma (MG-63) and glioma (U-251 MG) cells were irradiated with PBI with and without boronophenylalanine (BPA) enriched with &gt; 95% <sup>10</sup>B (<sup>10</sup>B-BPA) for BNCR and BPA with natural isotopic abundance of boron (80% <sup>11</sup>B + 20% <sup>10</sup>B; N-BPA) for BPCR. Sensitizer enhancement ratios (SERs) were obtained by comparing the doses that yielded a surviving fraction of 10% (D<sub>10</sub>). The D<sub>10</sub> values for PBI alone, PBI with <sup>10</sup>B-BPA, and PBI with N-BPA were 5.67, 4.85, and 5.51 and 5.21, 4.65, and 5.18 for MG-63 and U-251 MG cells, respectively. SERs of PBI with <sup>10</sup>B-BPA and N-BPA were 1.17 and 1.03 and 1.12 and 1.01 for MG-63 and U-251 MG cells, respectively. Our results indicate that <sup>10</sup>B-BPA-associated BNCR may be a better sensitizer for PBI than N-BPA-associated BPCR, which warrants further investigation into the clinical use of <sup>10</sup>B-enriched BPA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sensitization for proton beam therapy using 10B enriched and natural isotopic abundance of boronophenylalanine

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月16日

查看全文
  • Shintaro Shiba,
  • Takahiro Shimo,
  • Masashi Yamanaka,
  • Makoto Sakai,
  • Tatsuya Ohno,
  • Koichi Tokuuye,
  • Motoko Omura

摘要

Nuclear reactions between proton irradiation and boron via p + 11B→3α (boron proton-capture reaction; BPCR) and n + 10B→α+7Li (boron neutron-capture reaction; BNCR) enhance the cell-killing effects of proton beam irradiation (PBI); however, which reaction exerts superior sensitization effects remains unclear. Therefore, we evaluated the efficacy of the BPCR and BNCR in enhancing the cell-killing effects of PBI. Human osteosarcoma (MG-63) and glioma (U-251 MG) cells were irradiated with PBI with and without boronophenylalanine (BPA) enriched with > 95% 10B (10B-BPA) for BNCR and BPA with natural isotopic abundance of boron (80% 11B + 20% 10B; N-BPA) for BPCR. Sensitizer enhancement ratios (SERs) were obtained by comparing the doses that yielded a surviving fraction of 10% (D10). The D10 values for PBI alone, PBI with 10B-BPA, and PBI with N-BPA were 5.67, 4.85, and 5.51 and 5.21, 4.65, and 5.18 for MG-63 and U-251 MG cells, respectively. SERs of PBI with 10B-BPA and N-BPA were 1.17 and 1.03 and 1.12 and 1.01 for MG-63 and U-251 MG cells, respectively. Our results indicate that 10B-BPA-associated BNCR may be a better sensitizer for PBI than N-BPA-associated BPCR, which warrants further investigation into the clinical use of 10B-enriched BPA.